ImmuPharma plcLSE: IMM

Notification of Interim Results

· Issued by ImmuPharma plc

On 6ix: 6ix.com/news/notification-of-interim-results-21

Watch ImmuPharma's latest callImmupharma (LSE:IMM) — Corporate Update · Replay · Mar 20Read the transcript of Immupharma (LSE:IMM) — Corporate Update
RNS Number : 0613R
Immupharma PLC
19 September 2017
 

FOR IMMEDIATE RELEASE                                                                            19 SEPTEMBER 2017

ImmuPharma PLC

("ImmuPharma" or the "Company")

NOTIFICATION OF INTERIM RESULTS

Date: 27 September 2017

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, confirms that it will be announcing its Interim results for the six months ended 30 June 2017 on Wednesday 27 September 2017.

-Ends-

For further information please contact:

ImmuPharma plc (www.immupharma.org)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman

Lisa Baderoon, Head of Investor Relations

Twitter: @immupharma

+ 44 (0) 7721 413496

Northland Capital Partners Limited (Joint Broker)

Patrick Claridge, David Hignell, Jamie Spotswood, Corporate Finance

Rob Rees, Corporate Broking

+44 (0)20 3861 6625

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORXVLFFDKFLBBQ

ImmuPharma plc on 6ix

Story so far

Earlier from ImmuPharma

Later from ImmuPharma

All ImmuPharma news releases